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Clinical use of the beta-3 adrenoceptor agonist mirabegron in 
patients with overactive bladder syndrome 
 
Abstract 
Mirabegron is a beta-3 adrenoceptor agonist licensed for the treatment of 
overactive bladder symptoms, such as urinary urgency or urgency incontinence. 
Beta-3 adrenoceptor activation causes detrusor muscle relaxation, but 
mirabegron may also act by binding other targets in the bladder, and it may also 
reduce activity in sensory nerves. Phase 3 clinical trials (SCORPIO, ARIES, and 
CAPRICORN) evaluated mirabegron at various doses, demonstrating reduction 
from baseline to endpoint in mean incontinence episodes and mean number of 
micturitions per 24 hours (co-primary endpoints), along with health related 
quality of life and a range of secondary measures. Efficacy was seen in many 
patients who had previously discontinued antimuscarinic therapy on the grounds 
of lack of efficacy or poor tolerability. Treatment emergent adverse effects were 
documented in a long-term study (TAURUS), mostly being of mild or moderate 
severity. The most frequent adverse effects were hypertension, dry mouth, 
constipation, and headache, with a lower incidence of dry mouth than for the 
antimuscarinic active comparator. Efficacy and safety is not substantially different 
in older patients. A urodynamic safety study in men showed no consistent effect 
on voiding function, but a small increase in post void residual. Use of mirabegron 
in combination with alpha-adrenergic blockers does not appear to increase 
adverse effects. Dose reduction is needed in people with severe renal failure, or 
moderate hepatic failure. Dose adjustment is not needed in relation to food intake. 
Ongoing research is evaluating the potential for combination therapy with 
antimuscarinics. 
 
Introduction 
Lower urinary tract symptoms (LUTS) affecting urine storage include urinary 
urgency, urgency incontinence, increased daytime frequency and nocturia 1. 
Overactive bladder syndrome (OAB) is defined by the International Continence 
Society (ICS) as urinary urgency, with or without urgency incontinence, usually 
with increased daytime frequency and nocturia in the absence of proven infection 
or any other pathology 2.   It is a chronic symptom complex that can substantially 
impair quality of life (QoL). The prevalence of LUTS 3, OAB and urgency urinary 
incontinence is substantial, affecting both women and men, and resulting in 
considerable morbidity, personal cost and health economic burden 4, 5. 
Initial management uses conservative measures, such as fluid advice and bladder 
training 6. Drug therapy using antimuscarinics has long been the main-stay of the 
pharmacological treatment of OAB 6-8. However, compliance with these drugs is 
generally poor 9, due to perceived lack of efficacy and potential high rate of side 
effects. The emergence of new drugs and treatment regimens should improve 
patient persistence with treatment and acceptability. Development of Mirabegron 
(YM178), a β3-adrenoceptor (AR) agonist now offers a new pharmacotherapy 
option for the treatment of OAB 10. Mirabegron is available for clinical use as a 
modified release film coated tablet in an Oral Controlled Absorption System 
(OCAS), with two licensed dosage strengths of 25 mg and 50 mg. 
Mechanism of Action  
There are three sub-types of β-AR, with the β3-AR predominating in the detrusor 
muscle of some species 11, including the human bladder. β3-AR constitutes a high 
proportion of the β-AR mRNA in the human detrusor 12. Activation of these 
receptors elicits detrusor relaxation in bladder strips from various species 13, 
through generation of cyclic adenosine monophosphate 13, 14. β3-AR may also be 
present in other cell types of the bladder, such as urothelium 14-16 or interstitial 
cells 14. However, the role of their activation in the urothelium remains to be 
established 17.  
In animal studies, activation of β3-AR gives dose-dependent detrusor relaxation 
during the storage phase of the micturition cycle. Functionally, it increases 
intervoid interval and bladder compliance, while preserving voiding function in a 
rodent model 18. β3-AR are also suggested to inhibit sensory nerve activation, 
including activity in mechano-sensitive A-δelta fibres 19, and also reducing 
autonomous non voiding contractions  18, 20. β-AR activation can elicit release of 
nitric oxide by urothelium, giving a potential indirect mechanism which could 
further contribute to bladder relaxation 21, 22. A critical influence of β3-ARs in 
increasing bladder capacity, without changing micturition pressure or residual 
volume, may be mediated by inhibition of afferent nerve fibre activity 23.  
Pharmacokinetics- 
The marketed formulation of mirabegron is in an oral controlled absorption 
system (OCAS), with oral bioavailability in the range of 24 - 53% 24. The plasma 
protein binding is 71% 25. The time to reach maximum concentration after dosing 
is 3-4 hours, and the terminal elimination half-life is approximately 50 hours. The 
absolute bioavailability is dose-dependent and affected by gender 24. Interactions 
with cytochrome P450 (CYP) metabolism 26 27 are potentially relevant clinically. 
For example, drug-drug interactions may occur with concomitant administration 
of drugs that exert inducible (rifampin) or inhibitory (ketoconazole) effect on 
CYP3A4/5 24. CYP2D6 inhibition by mirabegron might alter the plasma exposure 
of metoprolol 24. One study has shown that combining mirabegron with an alpha 
adrenergic antagonist (tamsulosin) did not affect safety aspects, notably 
cardiovascular adverse effects, in 48 healthy men aged 44 years or older 28. 
Mirabegron OCAS tablets show a decrease in mirabegron plasma exposure with 
food that is independent of dose (50 or 100 mg) or gender, but dependent on meal 
composition; however, this does not warrant dose adjustment in clinical practice 
29. Pharmacokinetic changes observed in subjects with severe renal impairment 
or moderate hepatic impairment 25 mean that dose reduction is necessary. 
 
Clinical evidence of efficacy 
Mirabegron has been studied extensively, with more than 10,000 subjects 
involved in research studies over approximately 10 years. The safety and efficacy 
was evaluated in five global trials (two in phase 2 and three in phase 3) comparing 
various doses of mirabegron, either with placebo or tolterodine. 
BLOSSOM was a phase 2 proof of concept trial conducted in six European 
countries 30. The study randomised subjects to mirabegron at doses of 100 or 
150 mg twice daily (BID), placebo (BID), or tolterodine 4 mg extended release 
(ER) once daily for four weeks. The primary endpoint was change from baseline 
to end-of-treatment in mean number of micturition episodes per 24 hours. 
Mirabegron was superior to placebo and tolterodine, with mean reduction in 
micturition frequency of 2.2, 1.2 and 1.5 respectively. Mirabegron was superior to 
placebo in terms of mean volume voided, mean number of incontinence episodes, 
nocturia episodes and urgency episodes in 24 hours. There was no significant 
difference found between 100mg and 150 mg twice daily doses. 
The DRAGON study was a 12-week Phase 2B dose-ranging study conducted 
predominantly in Europe 31. 919 patients were randomised in six arms: placebo, 
mirabegron at doses of 25, 50, 100 or 200 mg once daily, or tolterodine as an active 
comparator. A dose-dependent decrease in mean number of micturitions per 24 
hours was seen with mirabegron, which was significant at the doses of 50mg and 
above as compared to placebo. 28% of people receiving mirabegron 50mg were 
classified as “responders” in terms of a reduction in voiding frequency (down to 
eight times daily or less). This compared with 19% for placebo and 19% for 
tolterodine. There were also significant improvements seen in secondary 
endpoints, such as mean number of urgency and urgency incontinence episodes, 
nocturia, and mean voided volume. Responses were evident at one week of 
treatment, with maximum efficacy gained at 8-12 weeks.  
The Phase 3 development programme comprised three studies; SCORPIO, ARIES, 
and CAPRICORN. These were large-scale, 12-week, multicenter, randomized, 
double-blind, parallel-group studies undertaken in Europe, Australia, and North 
America. They looked at two co-primary efficacy endpoints; the change from 
baseline to endpoint in mean incontinence episodes and mean number of 
micturitions per 24 hours. The study populations were adults of at least 18 years 
of age, with at least 8 micturitions per 24 hours, and at least three urgency 
episodes in their three day bladder diary, with or without urgency incontinence. 
Different doses of mirabegron were compared with placebo, and an active 
antimuscarinic comparator in some studies. 
SCORPIO 32 recruited 1,978 OAB patients and showed statistically significant 
improvement with 50 and 100mg mirabegron in both the measures. Although 
improvement was also seen in the tolterodine 4mg ER arm, it was not statistically 
significant. Significant improvement was also seen in mean number of urgency 
episodes and mean voided volume with mirabegron 50mg compared with 
placebo.  
ARIES enrolled 1,328 OAB patients, and significant improvement was seen in both 
co-primary end points, along with mean level of urgency, mean urgency 
incontinence episodes per 24 hours, and mean nocturia episodes 33.  
CAPRICORN included 1,306 patients, who were randomised to placebo, 
mirabegron 25mg or mirabegron 50mg 34. Mean reductions in incontinence 
episodes were 1.36 and 1.38 for mirabegron 25 mg and 50 mg, comparing with 
0.96 for the placebo group. Mean reductions in micturitions per 24 hours were 
1.65 and 1.60 for mirabegron 25 mg and 50 mg respectively (1.18 for placebo). 
Mirabegron 50 mg demonstrated significantly greater improvements versus 
placebo in mean volume voided/micturition, and this was not seen for mirabegron 
25 mg 34.  
Pooled analysis of the data from above trials reviewed outcomes of 3,542 patients 
randomised between placebo, mirabegron 50mg and mirabegron 100mg 35. This 
showed the reduction in mean number of incontinence episodes per 24 hours 
after 12 weeks of therapy was -1.10, -1.49 and -1.50 respectively. The equivalent 
reductions for number of micturitions per 24 hours were -1.20, -1.75 and -1.74 35. 
The higher dose did not appear to achieve additional benefit. The active doses also 
showed benefits in “dry rates” (zero incontinence episodes per 24 hours), at 
44.1% (mirabegron 50mg) and 46.4% (100mg) compared with 37.8% for placebo 
35. Statistically significant change in nocturia was seen, but the extent of clinical 
benefit is arguable (-0.55 voids per night for the active compound, -0.42 for 
placebo). Significant difference relative to placebo in these parameters was seen 
at four weeks. 
Mirabegron 25mg and 50mg were also shown to be effective in older patients with 
OAB (>65 or >75 years), demonstrating improvements in the primary endpoints 
36.  
Considering that antimuscarinic medications have long been the primary drug 
therapy for OAB, post hoc subgroup analysis looked at the effectiveness in 
treatment-naive patients and those who had previously discontinued 
antimuscarinic treatment (either from lack of efficacy, or due to difficulty 
tolerating the medication) 37. Response to mirabegron in terms of primary 
outcome measures was not affected by antecedent medication exposure (for those 
who discontinued due to poor efficacy), but it did significantly impact on response 
to the antimuscarinic active comparator. The placebo effect was found to be 
greater in the treatment-naive patients. Further information on this will be given 
by the BEYOND study 38, which studied 1,870 patients who were not satisfied by 
antimuscarinic therapy (on a treatment satisfaction Likert scale), and randomized 
them to either mirabegron 50mg or solifenacin 5mg.  
Overall, onset of response appears to be achieved for efficacy and quality of life 
measures at one month 39. Long term efficacy was evaluated in the TAURUS study, 
which was a randomized, double blind parallel group phase 3 trial, using 
mirabegron at doses of 50 or 100mg and tolterodine 4mg extended release as 
active comparator 40. In this trial, 2,444 patients were recruited. Efficacy 
endpoints were secondary measures, with improvements in OAB symptoms for 
both doses (50 and 100mg) seen by one month, using various measures, and 
maintained throughout the follow up period  
Health-related quality of life (HRQL) and treatment satisfaction were assessed in 
the mirabegron trials using various validated OAB-specific and general scales, 
such as the overactive bladder questionnaire (OAB-q) 41, the patient perception of 
bladder condition (PPBC) 42 and a treatment satisfaction visual analog scale (TS-
VAS). Significant improvement was demonstrated from baseline to final visit in 
these parameters of HRQL in all three of the main phase 3 studies. 
In the DRAGON study 31, International Consultation on Incontinence 
Questionnaire-Overactive Bladder (ICIQ-OAB) and ICIQ-OABqol questionnaires 
were used. Patient reported benefit was also evaluated, with the question “has the 
treatment been of any benefit to you?” The percentage of responders were 59.0%, 
65%, 65.8% and 70.8% for 25, 50, 100 and 200mg mirabegron respectively, 
compared with 51% for placebo and 55% of the tolterodine group.  
The studies included male patients, who generally made up between one quarter 
and one third of the study population in most of the reported studies, but the 
analyses did not separate findings according to gender.  
 Safety and Tolerability 
Mirabegron appears to have acceptable safety and tolerability in all the reported 
trials. In the BLOSSOM trial 31, the incidence of treatment emergent adverse effects 
(TEAEs) was 39.2% with mirabegron, compared to 36.4% and 48.4% with placebo 
and tolterodine respectively. Most of the adverse effects were minor or moderate 
in severity. The most commonly reported side effects were gastrointestinal 
disorders (13.8%), followed by headache (6.9%). Dizziness and palpitations were 
more common in mirabegron groups than the tolterodine group. The 
discontinuation rates due to adverse effects were 4.6% and 7.7% for the 
mirabegron groups, compared to 1.5% in the placebo group and 3.1% in the 
tolterodine group. 
In the DRAGON trial 31, the incidence of serious adverse events was reported as 
<2% of patients across the treatment groups. The most common side effects 
reported were again gastrointestinal (7.2%-8.3% with mirabegron vs 5.3% with 
placebo), including constipation, dry mouth, dyspepsia and nausea. Incidence of 
dry mouth was higher with tolterodine (3.5%) than mirabegron (1.8-3.0%). A 
dose-dependent small rise in pulse rate was also noted with mirabegron; this was 
not associated with any cardiovascular side effect, with no difference found in ECG 
parameters and blood pressure across the treatment groups. Discontinuation due 
to side effects was low, at 3.0% for placebo (3.0%), 2.4-5.3% for mirabegron and 
1.2% for tolterodine. There were no clinically significant episodes of acute 
retention observed with mirabegron.  
Pooled safety data from SCORPIO, ARIES, and CAPRICORN showed that the overall 
incidence of TEAEs was similar across the treatment groups and there was no 
evidence of a dose–response relationship among the mirabegron treatment 
groups for overall rates of TEAEs (mirabegron 25 mg 48.6%, mirabegron 50 mg 
47.1%, mirabegron 100 mg 43.3%, total mirabegron 46.0%, placebo 47.7% and 
tolterodine ER 4 mg 46.7%) 35. The most common side effects noted in the 
mirabegron groups were hypertension (7.3%), nasopharyngitis (3.4%), and 
urinary tract infection (3.0%). Dry mouth occurred more commonly in the 
tolterodine group (2.0% for the total mirabegron groups vs. 2.1% for placebo and 
10.1% for the tolterodine group). The discontinuation rates were; mirabegron 
25 mg 3.9%, mirabegron 50 mg 3.9%, mirabegron 100 mg 3.7%, total mirabegron 
3.8%, placebo 3.3%, and tolterodine ER 4 mg 4.4%.  
In the 12-month TAURUS study, the incidence of TEAEs was similar across the 
mirabegron 50 mg (59.7%), mirabegron 100 mg (61.3%), and tolterodine ER 4 mg 
(62.6%) groups. Most of the side effects were of mild or moderate severity. The 
most frequent were hypertension, constipation, and headache, occurring at a 
similar incidence across treatment groups, and dry mouth. Dry mouth had a higher 
incidence in the tolterodine group (8.6%, versus mirabegron 2.3-2.8%). 
Discontinuations due to AEs were comparable across treatment groups, occurring 
in 6.4%, 5.9%, and 6.0% of patients receiving mirabegron 50 mg, mirabegron 
100 mg, and tolterodine ER 4 mg, respectively. 
In older patients, 49% of placebo patients, and 55% on active compound reported 
a treatment emergent adverse effect. The three main adverse effects on active 
compound were hypertension, nasopharyngitis and urinary tract infection 36. Dry 
mouth and constipation did not differ from placebo.  
For men, in whom bladder outlet obstruction might be a feature due to benign 
prostate enlargement, the possibility of impairing voiding function as a 
consequence of administering medications to aid urine storage has to be 
considered. A urodynamic safety study was undertaken in 200 men receiving 
mirabegron 50 or 100mg or placebo for 12 weeks 43. Maximum flow rate and 
detrusor pressure at maximum flow were not significantly impaired by active 
treatment. A small increase in post void residual was seen for mirabegron 100mg. 
Acute urinary retention occurred in one man on placebo and one on mirabegron 
100mg. The proportion of patients experiencing ≥150 ml change from baseline in 
post void residual volume was lower in the mirabegron groups compared with 
tolterodine: mirabegron 25 mg (0%), mirabegron 50 mg (0.3%), mirabegron 
100 mg (0.4%), placebo (0.7%), and tolterodine ER 4 mg (0.8%) in the pooled 
analysis of the phase III trials 35. 
Mirabegron was shown not to raise intraocular pressure (IOP) after treatment 
with 100mg daily for 8 weeks in healthy volunteers 44, which is advantageous 
when considering that closed-angle glaucoma is a contra-indication to 
antimuscarinic therapy.    
 
Combination therapy 
Management of LUTS is increasingly reliant on combination pharmaceutical 
therapy, and the introduction of a new drug class for OAB offers further 
opportunities for combinations aiming to increase efficacy or reduce side effects. 
The SYMPHONY study 45 was a dose ranging phase 2 study using a range of 
permutations combining mirabegron with solifenacin. Several combination doses 
achieved greater improvements in mean voided volume, micturition frequency, 
and urgency than solifenacin monotherapy. The BESIDE study 46 has recently 
completed recruitment, and was designed to see if adding mirabegron to an 
antimuscarinic treatment (solifenacin) will be more effective in controlling 
incontinence than when using the antimuscarinic treatment alone.  
In male LUTS, combinations of antimuscarinic medication and alpha adrenergic 
blockers are routinely used in refractory cases (for example solifenacin and 
tamsulosin 47). Combining mirabegron with alpha adrenergic blockers is likely to 
be considered in developing the therapeutic area. Efficacy assessments for such 
combinations have recently been reported in men receiving mirabegron with 
tamsulosin (0.2mg), in whom the OAB Symptom Score (OABSS) fell by -2.21 for 
the combination group and by -0.87 in the tamsulosin monotherapy group 48. The 
safety aspects of combining mirabegron with tamsulosin have previously been 
reported in a separate study 28. 
 
Conclusions  
Mirabegron is a first-in-class β-3 agonist for treatment of OAB in women or men, 
which appears to have good efficacy and tolerability. It can be used in patients who 
have discontinued antimuscarinic therapy, or who have contraindications for 
antimuscarinics. Development of combination therapies may further extend the 
management options in OAB in the future.  
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